Business Wire

Svante Secures Commercial Supply of MOF Advanced Sorbent Materials with BASF for Carbon Capture Market

Share

Svante announced today that it has entered into an arm’s length Commercial Supply Agreement with BASF to scale up its proprietary sorbent material, Calgary Framework 20 (CALF-20), used in Svante’s carbon capture process. This metal-organic framework (MOF) sorbent can capture up to 95% of carbon dioxide (CO2) emitted from industrial sources, such as cement and blue hydrogen plants, using rapid solid adsorption and low-pressure steam.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231010178949/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Svante's metal-organic framework (MOF), CALF-28, used for the company's novel carbon capture filter technology, is to be manufactured by BASF at commercial scale. (Photo: Business Wire)

Svante has pioneered carbon capture and removal technology using structured adsorbent beds, known as “filters”. The company is the most advanced industry player in the use of solid sorbents for carbon capture, with the world’s first commercially available MOF nanomaterial filter manufacturing facility in Vancouver, BC. This commercial supply agreement with BASF will unlock the next phase of Svante’s growth, scaling carbon capture filter manufacturing up to multi-million-tonne capacity and implementing hundreds of large-scale carbon capture and storage (CCS) facilities by 2030.

Svante’s unique modular and environmentally responsible solid sorbent technology is designed to capture CO2 from industrial flue gas. It then concentrates it into a high purity 95% pipeline-grade) CO2 and releases it for safe storage or further industrial use. Its unique approach is tailored specifically to the challenges of separating CO2 from nitrogen in diluted flue gas, which is typically emitted in large volumes at low pressures and in dilute concentrations. Svante’s technology will play a key role in decarbonizing industrial activity in diverse fields including hydrogen, pulp and paper, cement, steel, aluminum, and chemicals.

Svante and BASF have been working collaboratively for the last two years to scale up CALF-20, which acts as a sponge for adsorbing CO2. Results of their research, published in the international peer-reviewed journal, Science, in December 2021, demonstrated CALF-20's unique resistance to oxidation and water vapor, which allows CO2 to be captured at a low cost, using Svante’s proprietary structured adsorbent filters.

Solid sorbents are a step change for carbon capture, but the challenge is to merge all of their desirable features into a robust framework material with a low manufacturing cost. CALF-20 coupled with Svante’s filter addresses this challenge and captures CO2 with high capacity and selectivity over water.

“For high-performance CO2 capture and removal, steam stripping — where direct contact steam is used to flush CO2 out of the sorbent — has been a sort of ‘holy grail’ in the field. It is seen as the most effective way to do it,” said Claude Letourneau, President & CEO of Svante. “This MOF material, combined with our proprietary structured adsorption filters, is a game-changer for the carbon capture and removal industry. We have the right technology to reduce the capital cost of CO2 capture. It is modular and adaptable. Now, we need to scale up this technology and commercialize it to create a viable carbon management industry at gigaton scale”.

Svante, in collaboration with BASF, has successfully scaled up the CALF-20 MOF sorbent from laboratory to industrial scale by using a simple low-temperature process in accordance with green chemistry principles. Scalability and low cost of solid sorbents are imperative to the wide adoption of CCS. Up until now, large-scale production of MOF materials at low cost has been a barrier for the gas separation industry.

In addition to scaling up its CALF-20 manufacturing process, Svante has developed a high-volume and low-cost roll-to-roll process for coating the sorbent onto sheets of laminate, which it calls “Sorbent on a Roll”. The laminate is then stacked into high-performance filters, which are now available for both industrial point-source capture and direct air capture.

About Svante

Headquartered in Vancouver, BC, Canada, Svante is a purpose-driven, leading carbon capture and removal solutions provider. The company makes nanoengineered filters and modular rotary contactor machines that capture and remove CO2 in an environmentally responsible way from industrial emissions and the air. Svante is on the 2023 Global Cleantech 100, the XPRIZE Foundation’s XB100 — World’s Top 100 Deep Tech Companies, and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies in Canada. To learn more about Svante, visit www.svanteinc.com and follow Svante on LinkedIn or Twitter @svantesolutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Svante
Colleen Nitta
Director of Marketing & Communications
cnitta@svanteinc.com
604-970-2813

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ

Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press Release

Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c

BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande

Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar

FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release

The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye